These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 10506095)

  • 21. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
    Ramsaransing GS; De Keyser J
    Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
    Katz Sand I; Krieger S; Farrell C; Miller AE
    Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of multiple sclerosis relapses on progression diminishes with time.
    Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
    Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics of progressive relapsing multiple sclerosis.
    Tullman MJ; Oshinsky RJ; Lublin FD; Cutter GR
    Mult Scler; 2004 Aug; 10(4):451-4. PubMed ID: 15327045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.
    Langer-Gould A; Popat RA; Huang SM; Cobb K; Fontoura P; Gould MK; Nelson LM
    Arch Neurol; 2006 Dec; 63(12):1686-91. PubMed ID: 17172607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
    Kalincik T; Vivek V; Jokubaitis V; Lechner-Scott J; Trojano M; Izquierdo G; Lugaresi A; Grand'maison F; Hupperts R; Oreja-Guevara C; Bergamaschi R; Iuliano G; Alroughani R; Van Pesch V; Amato MP; Slee M; Verheul F; Fernandez-Bolanos R; Fiol M; Spitaleri DL; Cristiano E; Gray O; Cabrera-Gomez JA; Shaygannejad V; Herbert J; Vucic S; Needham M; Petkovska-Boskova T; Sirbu CA; Duquette P; Girard M; Grammond P; Boz C; Giuliani G; Rio ME; Barnett M; Flechter S; Moore F; Singhal B; Bacile EA; Saladino ML; Shaw C; Skromne E; Poehlau D; Vella N; Spelman T; Liew D; Kilpatrick TJ; Butzkueven H;
    Brain; 2013 Dec; 136(Pt 12):3609-17. PubMed ID: 24142147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous prediction of secondary progression in the individual course of multiple sclerosis.
    Skoog B; Tedeholm H; Runmarker B; Odén A; Andersen O
    Mult Scler Relat Disord; 2014 Sep; 3(5):584-92. PubMed ID: 26265270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Muraro PA; Ebers GC
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):67-75. PubMed ID: 23486991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining secondary progressive multiple sclerosis.
    Lorscheider J; Buzzard K; Jokubaitis V; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Alroughani R; Sola P; Boz C; Pucci E; Lechner-Scott J; Bergamaschi R; Oreja-Guevara C; Iuliano G; Van Pesch V; Granella F; Ramo-Tello C; Spitaleri D; Petersen T; Slee M; Verheul F; Ampapa R; Amato MP; McCombe P; Vucic S; Sánchez Menoyo JL; Cristiano E; Barnett MH; Hodgkinson S; Olascoaga J; Saladino ML; Gray O; Shaw C; Moore F; Butzkueven H; Kalincik T;
    Brain; 2016 Sep; 139(Pt 9):2395-405. PubMed ID: 27401521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
    Kalincik T; Manouchehrinia A; Sobisek L; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Girard M; Prat A; Duquette P; Grammond P; Sola P; Hupperts R; Grand'Maison F; Pucci E; Boz C; Alroughani R; Van Pesch V; Lechner-Scott J; Terzi M; Bergamaschi R; Iuliano G; Granella F; Spitaleri D; Shaygannejad V; Oreja-Guevara C; Slee M; Ampapa R; Verheul F; McCombe P; Olascoaga J; Amato MP; Vucic S; Hodgkinson S; Ramo-Tello C; Flechter S; Cristiano E; Rozsa C; Moore F; Luis Sanchez-Menoyo J; Laura Saladino M; Barnett M; Hillert J; Butzkueven H;
    Brain; 2017 Sep; 140(9):2426-2443. PubMed ID: 29050389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of primary progressive multiple sclerosis.
    Ebers GC
    Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting risk of secondary progression in multiple sclerosis: A nomogram.
    Manouchehrinia A; Zhu F; Piani-Meier D; Lange M; Silva DG; Carruthers R; Glaser A; Kingwell E; Tremlett H; Hillert J
    Mult Scler; 2019 Jul; 25(8):1102-1112. PubMed ID: 29911467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. THE RELATIONSHIP BETWEEN THE DURATION OF REMISSIONS AFTER THE ONSET, THE SEVERITY OF THE RELAPSES AGAINST THE BACKGROUND OF DIFFERENT DURATION OF THE RELAPSING STAGE AND THE NATURE OF THE PROGNOSIS IN SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS.
    Voloshina N; Vasilovsky V; Negreba T; Kirzhner V; Voloshyn-Haponov I
    Georgian Med News; 2023; (340-341):180-184. PubMed ID: 37805895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining reliable disability outcomes in multiple sclerosis.
    Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
    Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.